About My Health Careers Internship MedBlogs Contact us

New Therapy Target for Schizophrenia Identified in the Brain

by VR Sreeraman on November 6, 2008 at 4:53 PM
Font : A-A+

 New Therapy Target for Schizophrenia Identified in the Brain

Researchers excited about the identification of a brain region that responds to more than one type of anti-psychotic drug, as the feel that it could expand the options for controlling schizophrenia.

The researchers say that their findings are the first to illustrate that the orbitofrontal cortex-a brain region responsible for cognitive activity such as decision making-could be a promising target for developing future antipsychotic drugs, even those that have very different mechanisms of action.


Bita Moghaddam, a professor in the Department of Neuroscience in Pitt's School of Arts and Sciences, says that the study has shown that schizophrenia-like activity in the orbitofrontal cortex could be triggered by the two different neurotransmitters linked to schizophrenia: dopamine and glutamate.

The study's lead author revealed that brain activity was later normalised by established antipsychotic medications that regulate only dopamine, and by experimental treatments that specifically target glutamate.

"The orbitofrontal cortex is an area that's been somewhat neglected in schizophrenia research. This study should encourage researchers to focus on this brain region in imaging and other human studies, and also to use as a model for developing antipsychotic drugs," Moghaddam said.

"Schizophrenia appears to be caused by very diverse and sometimes rare genetic mutations. Diverse mutations can end up causing the same disease if they disrupt the function of a common group of neurons or networks of neurons. We think that the key to understanding the pathophysiology of schizophrenia and finding better treatments is to identify these networks. This data suggests that the orbitofrontal cortex may be a critical component in networks affected by schizophrenia," the researcher added.

Working with UPMC neurology resident Houman Homayoun, Moghaddam first established that both dopamine and glutamate could produce schizophrenia-like symptoms in the orbitofrontal cortex.

The researchers said that previous studies had already shown that under-functioning glutamate receptors known as NMDA receptors could produce schizophrenia-like symptoms.

In the current study, according to the researchers, it was found that stunting the NMDA receptors could lead to schizophrenia-like effects in the orbitofrontal cortex.

The researchers also used a dose of amphetamine to simulate dopamine-related schizophrenia symptoms in the orbitofrontal cortex, as schizophrenia is often linked to an excess of dopamine in the brain.

Moghaddam and Homayoun then tested the currently prescribed medication-a treatment developed more than 50 years ago that targets neural receptors of dopamine-and new experimental drugs that work on the glutamate system.

They observed that both medications normalized brain activity.

The study has been published in the online edition of the journal Proceedings of National Academy of Sciences.

Source: ANI

News A-Z
News Category
What's New on Medindia
Woman with Rare Spinal Cord Defect from Birth Sues Doctor
World AIDS Day 2021 - End Inequalities, End AIDS
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Parkinsons Disease Schizophrenia Parkinsons Disease Surgical Treatment Reiki and Pranic Healing Brain Brain Facts Mental Health - Neurosis vs Psychosis Schizoaffective Disorder Mind-wandering Paranoia 

Recommended Reading
Schizophrenia is a mental disorder characterized by symptoms of thought, behavior and social ......
Know Your Nervous System
The Central nervous system consists of the brain, the spinal cord, and the body's nerve network. ......
Enzyme That may Contribute to Schizophrenia, Psychiatric Disorders Identified
A new study on mice has found that the lack of an enzyme that contributes to Alzheimer's disease ......
Psychotherapy Proves Beneficial in the Long Run
A new report has said that long-term psychodynamic psychotherapy (LTPP) is better than short-term .....
Mental Health - Neurosis vs Psychosis
Mental well-being is a concern and abnormal coping of emotions can lead to neurosis or psychosis. Me...
Mind wandering is a spontaneous and unintentional shifting of attention of thoughts from a primary t...
Paranoia is a false belief where the individual feels unfairly targeted or persecuted by everyone el...
Parkinsons Disease
Parkinson’s disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. ...
Schizoaffective Disorder
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms that...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use